TY - JOUR
T1 - Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients
T2 - clinical findings and long-term follow-up
AU - Alijotas-Reig, Jaume
AU - Garcia-Gimenez, Victor
AU - Vilardell-Tarres, Miquel
N1 - Copyright 2009 S. Karger AG, Basel.
PY - 2009
Y1 - 2009
N2 - BACKGROUND: It has been thought that poly-L-lactic acid (PLLA) injections do not have inflammatory side effects. Recent evidence shows that local/regional/systemic delayed adverse effects may appear with its use.OBJECTIVE: To evaluate the clinical complaints, treatment response and long-term follow-up of non-HIV patients with delayed immune-mediated adverse effects related to PLLA injections.METHODS: Prospective, case series study of 10 patients with delayed adverse effects related to PLLA injections. The inclusion criterion was defined as the onset at least 6 months after PLLA use, with 1 or more of the following clinical signs: oedema, skin induration, swelling/tender nodules with or without discharge of pus or filler material. Several systemic manifestations were also included. Patients with immediate side effects were excluded. Patients underwent clinical management and long-term follow-up.RESULTS: The average latency period to the onset of symptoms was 19.2 months (range: 6-60). Tender, inflammatory nodules and facial oedema were commonly seen. One case presented a systemic granulomatous disorder as a complication. After 50.2 months of average follow-up (range: 38-78), 5 patients are in remission, 4 have recurrent bouts and the last case has been lost to follow-up.CONCLUSION: Although infrequently, local and/or regional and/or systemic delayed and recurrent granulomatous reactions may complicate PLLA gel injections.
AB - BACKGROUND: It has been thought that poly-L-lactic acid (PLLA) injections do not have inflammatory side effects. Recent evidence shows that local/regional/systemic delayed adverse effects may appear with its use.OBJECTIVE: To evaluate the clinical complaints, treatment response and long-term follow-up of non-HIV patients with delayed immune-mediated adverse effects related to PLLA injections.METHODS: Prospective, case series study of 10 patients with delayed adverse effects related to PLLA injections. The inclusion criterion was defined as the onset at least 6 months after PLLA use, with 1 or more of the following clinical signs: oedema, skin induration, swelling/tender nodules with or without discharge of pus or filler material. Several systemic manifestations were also included. Patients with immediate side effects were excluded. Patients underwent clinical management and long-term follow-up.RESULTS: The average latency period to the onset of symptoms was 19.2 months (range: 6-60). Tender, inflammatory nodules and facial oedema were commonly seen. One case presented a systemic granulomatous disorder as a complication. After 50.2 months of average follow-up (range: 38-78), 5 patients are in remission, 4 have recurrent bouts and the last case has been lost to follow-up.CONCLUSION: Although infrequently, local and/or regional and/or systemic delayed and recurrent granulomatous reactions may complicate PLLA gel injections.
KW - Adult
KW - Aged
KW - Biocompatible Materials/administration & dosage
KW - Cohort Studies
KW - Cosmetic Techniques
KW - Edema/chemically induced
KW - Face
KW - Female
KW - Follow-Up Studies
KW - Granuloma, Foreign-Body/etiology
KW - HIV Infections/complications
KW - Humans
KW - Hypersensitivity, Delayed/chemically induced
KW - Injections
KW - Lactic Acid/administration & dosage
KW - Middle Aged
KW - Polyesters
KW - Polymers/administration & dosage
KW - Prospective Studies
KW - Rejuvenation
KW - Treatment Outcome
U2 - 10.1159/000243804
DO - 10.1159/000243804
M3 - Article
C2 - 19797889
SN - 1018-8665
VL - 219
SP - 303
EP - 308
JO - Dermatology (Basel, Switzerland)
JF - Dermatology (Basel, Switzerland)
IS - 4
ER -